Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea

Samir K. Ballas, Mary J. Marcolina, George J Dover, Franca B. Barton

Research output: Contribution to journalArticle

Abstract

In this project we have prospectively studied the erythropoietic activity in patients with sickle Cell anaemia (SS) before and after treatment with hydroxyurea (HU). Some of the patients were enrolled in a double-blind placebo controlled trial of HU in patients with SS and others were enrolled in an open label study. Determinants of erythropoietic activity included the reticulocyte count, red blood cell (RBC) survival by the 51Cr method, plasma 59Fe clearance, plasma iron turnover (PIT), erythron transferrin uptake (ETU), RBC production/destruction rate, and RBC Fe utilization. Therapy with HU increased the mean corpuscular volume (MCV), haemoglobin (Hb)F, RBC survival and t(1/2) 59Fe clearance; it decreased the reticulocyte count, the white blood cell (WBC) count, ETU, and the PIT. Most of the changes in parameters of erythropoiesis could be explained by the increase in 51Cr RBC survival after therapy with HU. Together the data showed that in selected patients the net effect of HU on Hb level was a function of the difference between the suppressive effect of HU (decreased RBC production) and the increase in RBC survival. In the majority of patients who responded to HU, there was a preferential effect on RBC survival.

Original languageEnglish (US)
Pages (from-to)491-496
Number of pages6
JournalBritish Journal of Haematology
Volume105
Issue number2
StatePublished - 1999

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Erythrocytes
Cell Survival
Reticulocyte Count
Erythrocyte Indices
Therapeutics
Transferrin
Iron
Fetal Hemoglobin
Erythropoiesis
Leukocyte Count
Hemoglobins
Placebos

Keywords

  • Erythrokinetics
  • Erythropoietic activity
  • Hydroxyurea
  • Red cell survival
  • Sickle cell anaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. / Ballas, Samir K.; Marcolina, Mary J.; Dover, George J; Barton, Franca B.

In: British Journal of Haematology, Vol. 105, No. 2, 1999, p. 491-496.

Research output: Contribution to journalArticle

Ballas, Samir K. ; Marcolina, Mary J. ; Dover, George J ; Barton, Franca B. / Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. In: British Journal of Haematology. 1999 ; Vol. 105, No. 2. pp. 491-496.
@article{9f84340db5224d508a1d470fa6e78aad,
title = "Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea",
abstract = "In this project we have prospectively studied the erythropoietic activity in patients with sickle Cell anaemia (SS) before and after treatment with hydroxyurea (HU). Some of the patients were enrolled in a double-blind placebo controlled trial of HU in patients with SS and others were enrolled in an open label study. Determinants of erythropoietic activity included the reticulocyte count, red blood cell (RBC) survival by the 51Cr method, plasma 59Fe clearance, plasma iron turnover (PIT), erythron transferrin uptake (ETU), RBC production/destruction rate, and RBC Fe utilization. Therapy with HU increased the mean corpuscular volume (MCV), haemoglobin (Hb)F, RBC survival and t(1/2) 59Fe clearance; it decreased the reticulocyte count, the white blood cell (WBC) count, ETU, and the PIT. Most of the changes in parameters of erythropoiesis could be explained by the increase in 51Cr RBC survival after therapy with HU. Together the data showed that in selected patients the net effect of HU on Hb level was a function of the difference between the suppressive effect of HU (decreased RBC production) and the increase in RBC survival. In the majority of patients who responded to HU, there was a preferential effect on RBC survival.",
keywords = "Erythrokinetics, Erythropoietic activity, Hydroxyurea, Red cell survival, Sickle cell anaemia",
author = "Ballas, {Samir K.} and Marcolina, {Mary J.} and Dover, {George J} and Barton, {Franca B.}",
year = "1999",
language = "English (US)",
volume = "105",
pages = "491--496",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea

AU - Ballas, Samir K.

AU - Marcolina, Mary J.

AU - Dover, George J

AU - Barton, Franca B.

PY - 1999

Y1 - 1999

N2 - In this project we have prospectively studied the erythropoietic activity in patients with sickle Cell anaemia (SS) before and after treatment with hydroxyurea (HU). Some of the patients were enrolled in a double-blind placebo controlled trial of HU in patients with SS and others were enrolled in an open label study. Determinants of erythropoietic activity included the reticulocyte count, red blood cell (RBC) survival by the 51Cr method, plasma 59Fe clearance, plasma iron turnover (PIT), erythron transferrin uptake (ETU), RBC production/destruction rate, and RBC Fe utilization. Therapy with HU increased the mean corpuscular volume (MCV), haemoglobin (Hb)F, RBC survival and t(1/2) 59Fe clearance; it decreased the reticulocyte count, the white blood cell (WBC) count, ETU, and the PIT. Most of the changes in parameters of erythropoiesis could be explained by the increase in 51Cr RBC survival after therapy with HU. Together the data showed that in selected patients the net effect of HU on Hb level was a function of the difference between the suppressive effect of HU (decreased RBC production) and the increase in RBC survival. In the majority of patients who responded to HU, there was a preferential effect on RBC survival.

AB - In this project we have prospectively studied the erythropoietic activity in patients with sickle Cell anaemia (SS) before and after treatment with hydroxyurea (HU). Some of the patients were enrolled in a double-blind placebo controlled trial of HU in patients with SS and others were enrolled in an open label study. Determinants of erythropoietic activity included the reticulocyte count, red blood cell (RBC) survival by the 51Cr method, plasma 59Fe clearance, plasma iron turnover (PIT), erythron transferrin uptake (ETU), RBC production/destruction rate, and RBC Fe utilization. Therapy with HU increased the mean corpuscular volume (MCV), haemoglobin (Hb)F, RBC survival and t(1/2) 59Fe clearance; it decreased the reticulocyte count, the white blood cell (WBC) count, ETU, and the PIT. Most of the changes in parameters of erythropoiesis could be explained by the increase in 51Cr RBC survival after therapy with HU. Together the data showed that in selected patients the net effect of HU on Hb level was a function of the difference between the suppressive effect of HU (decreased RBC production) and the increase in RBC survival. In the majority of patients who responded to HU, there was a preferential effect on RBC survival.

KW - Erythrokinetics

KW - Erythropoietic activity

KW - Hydroxyurea

KW - Red cell survival

KW - Sickle cell anaemia

UR - http://www.scopus.com/inward/record.url?scp=0032946891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032946891&partnerID=8YFLogxK

M3 - Article

VL - 105

SP - 491

EP - 496

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -